Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anna Gil Sánchez, Eugenia Lacasa Andrade, Joan Valls Marsal, Lourdes Assens Tauste, Cristina González Mingot, Jorge Lecina Monge, Margarita Casalilla Puértolas, Nuria Sáez Calero, Albert Sacristán Argemí, Blanca Guiu Badia, Silvia Peralta Moncusí, Hugo Gonzalo Benito, Lara Nogueras Peñabad, Marta Lordan Pujol, Mónica Nieves i Collado & Luis Brieva Ruiz. (2017) A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients. International Journal of Neuroscience 127:5, pages 404-411.
Read now
Read now
Tjalf Ziemssen, Natalia Ashtamker, Svetlana Rubinchick, Volker Knappertz & Giancarlo Comi. (2017) Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opinion on Drug Safety 16:2, pages 247-255.
Read now
Read now
Ghasem Ghalamfarsa, Mohammad Hojjat-Farsangi, Mousa Mohammadnia-Afrouzi, Enayat Anvari, Shohreh Farhadi, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2016) Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis. Journal of Immunotoxicology 13:5, pages 603-619.
Read now
Read now
Aaron E Miller. (2015) Teriflunomide for the treatment of relapsing–remitting multiple sclerosis. Expert Review of Clinical Immunology 11:2, pages 181-194.
Read now
Read now
Articles from other publishers (4)
Zeinab Jan, Samaneh Mollazadeh, Khalil Abnous, Seyed Mohammad Taghdisi, Abolghasem Danesh, Mohammad Ramezani & Mona Alibolandi. (2022) Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics 19:7, pages 1952-1976.
Crossref
Crossref
Wolfgang Freund. (2022) Hautveränderungen unter Glatirameracetat bei MS. NeuroTransmitter 33:5, pages 33-35.
Crossref
Crossref
Chiara Zecca, G. Bellavia, L. Brambilla, L. P. Gutierrez, C. Gerardi, A. M. Fiori, L. R. Bernardini, G. Camera, G. Disanto, L. Petrini, J. Perugini, C. G. Antozzi, V. Torri Clerici, A. Bellino, P. A. Confalonieri, C. Gobbi, R. E. Mantegazza & S. Rossi. (2018) Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?. CNS Drugs 32:7, pages 653-660.
Crossref
Crossref
Olga Zapletalová. (2016) Glatiramer acetate: long-term immunomodulatory therapy in multiple sclerosis - safety, efficacy,. Neurologie pro praxi 17:2, pages 95-99.
Crossref
Crossref